Global private equity and venture capital news and research

PureTech Ventures adds ex-Pfizer exec John LaMattina as senior partner

11 Nov 2009

PureTech Ventures, a firm focused on creation and early stage investment in therapeutics, medical devices, diagnostics, and research technologies, has added John LaMattina as a senior partner. LaMattina was previously president of Pfizer Global Research & Development and executive vice president of pharmaceuticals giant Pfizer, Inc.

Along with his 30-year career at Pfizer, LaMattina also serves on the board of directors of Human Genome Sciences and Neurogen and as chairman of the strategic advisory committee for Bilcare.

LaMatina said, “The opportunity to work with world class scientists on cutting edge programmes has always been my passion. I look forward to having stimulating interactions in an entrepreneurial atmosphere with my colleagues at PureTech and to building programmes that can truly impact the future of medicine.”

Coinciding with the addition of LaMattina, PureTech also promoted two employees, Eric Elenko and Steve Muniz, to partners as an expansion of their operational leadership team.

Copyright © 2009 AltAssets


Join the Private Equity & VC Fundraising & IR Group on LinkedIn. For LPs and GPs with an interest in private equity and venture capital fundraising, investor relations and marketing.

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014